Affivant: Pioneering Innate Immune Cell Engagers for the Future of Cancer Therapy
Cancer remains one of the most pressing medical challenges of our time, and despite significant progress in immuno-oncology, many patients with solid tumors continue to face limited treatment options. The biotech world has long been dominated by therapies targeting the adaptive immune system, especially T-cell–based strategies like checkpoint inhibitors and CAR-T therapies. While groundbreaking, these … Read more